Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: A validation study with image-guided stereotactic biopsy

Shanshan Jiang, Charles G. Eberhart, Michael Lim, Hye Young Heo, Yi Zhang, Lindsay Blair, Zhibo Wen, Matthias Holdhoff, Doris Lin, Peng Huang, Huamin Qin, Alfredo Quinones-Hinojosa, Jon D. Weingart, Peter B. Barker, Martin G. Pomper, John Laterra, Peter C.M. Van Zijl, Jaishri O. Blakeley, Jinyuan Zhou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: To quantify the accuracy of amide proton trans-the same tumor. Of the 64 total specimens, 20 specimens were fer-weighted (APTw) MRI for identifying active glioma after active glioma, 27 mixed active and quiescent glioma, and 17 treatment via radiographically guided stereotactic tissue quiescent/no identifiable tumor. APTw signal intensity and validation. histopathologic assignment, cellularity, and proliferation Experimental Design: Twenty-one patients who were index had significant positive correlations (R ¼ 0.651, referred for surgery for MRI features concerning for tumor 0.580, and 0.458, respectively; all P < 0.001). ROC analysis progression versus treatment effect underwent preoperative with a 1.79% APTw intensity cutoff differentiated active from APTw imaging. Stereotactic biopsy samples were taken from nonactive tumor (AUC of 0.881) with 85.1% sensitivity and regions of interest with varying APTw signal intensities. 94.1% specificity. Analysis of clinical pathology showed the The relationship between final clinical pathology and the mean APTw intensity for each patient had 94.4% sensitivity histopathology of each of the 64 specimens was analyzed and 100% positive predictive value for identifying recurrent relative to APTw results. Analysis of confirmed recurrent tumor glioma at this cutoff. or treatment effect tissue was used to perform ROC analysis. Conclusions: APTw imaging hyperintensity may be a mark-Results: Eighteen of 21 patients had recurrent tumor, and 3 er of active malignant glioma. It is able to distinguish between had treatment effect on clinical pathology. In 12 patients, there regions of heterogeneous abnormality on anatomic brain MRI were multiple histopathologic assignments confirmed within with high sensitivity and specificity.

Original languageEnglish (US)
Pages (from-to)552-561
Number of pages10
JournalClinical Cancer Research
Volume25
Issue number2
DOIs
StatePublished - Jan 15 2019
Externally publishedYes

Fingerprint

Image-Guided Biopsy
Validation Studies
Amides
Glioma
Protons
Clinical Pathology
Neoplasms
ROC Curve
Therapeutics
Area Under Curve
Research Design
Biopsy
Sensitivity and Specificity
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging : A validation study with image-guided stereotactic biopsy. / Jiang, Shanshan; Eberhart, Charles G.; Lim, Michael; Heo, Hye Young; Zhang, Yi; Blair, Lindsay; Wen, Zhibo; Holdhoff, Matthias; Lin, Doris; Huang, Peng; Qin, Huamin; Quinones-Hinojosa, Alfredo; Weingart, Jon D.; Barker, Peter B.; Pomper, Martin G.; Laterra, John; Van Zijl, Peter C.M.; Blakeley, Jaishri O.; Zhou, Jinyuan.

In: Clinical Cancer Research, Vol. 25, No. 2, 15.01.2019, p. 552-561.

Research output: Contribution to journalArticle

Jiang, S, Eberhart, CG, Lim, M, Heo, HY, Zhang, Y, Blair, L, Wen, Z, Holdhoff, M, Lin, D, Huang, P, Qin, H, Quinones-Hinojosa, A, Weingart, JD, Barker, PB, Pomper, MG, Laterra, J, Van Zijl, PCM, Blakeley, JO & Zhou, J 2019, 'Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: A validation study with image-guided stereotactic biopsy', Clinical Cancer Research, vol. 25, no. 2, pp. 552-561. https://doi.org/10.1158/1078-0432.CCR-18-1233
Jiang, Shanshan ; Eberhart, Charles G. ; Lim, Michael ; Heo, Hye Young ; Zhang, Yi ; Blair, Lindsay ; Wen, Zhibo ; Holdhoff, Matthias ; Lin, Doris ; Huang, Peng ; Qin, Huamin ; Quinones-Hinojosa, Alfredo ; Weingart, Jon D. ; Barker, Peter B. ; Pomper, Martin G. ; Laterra, John ; Van Zijl, Peter C.M. ; Blakeley, Jaishri O. ; Zhou, Jinyuan. / Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging : A validation study with image-guided stereotactic biopsy. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 2. pp. 552-561.
@article{396677662db24ceaac6542e02ec69dbf,
title = "Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: A validation study with image-guided stereotactic biopsy",
abstract = "Purpose: To quantify the accuracy of amide proton trans-the same tumor. Of the 64 total specimens, 20 specimens were fer-weighted (APTw) MRI for identifying active glioma after active glioma, 27 mixed active and quiescent glioma, and 17 treatment via radiographically guided stereotactic tissue quiescent/no identifiable tumor. APTw signal intensity and validation. histopathologic assignment, cellularity, and proliferation Experimental Design: Twenty-one patients who were index had significant positive correlations (R ¼ 0.651, referred for surgery for MRI features concerning for tumor 0.580, and 0.458, respectively; all P < 0.001). ROC analysis progression versus treatment effect underwent preoperative with a 1.79{\%} APTw intensity cutoff differentiated active from APTw imaging. Stereotactic biopsy samples were taken from nonactive tumor (AUC of 0.881) with 85.1{\%} sensitivity and regions of interest with varying APTw signal intensities. 94.1{\%} specificity. Analysis of clinical pathology showed the The relationship between final clinical pathology and the mean APTw intensity for each patient had 94.4{\%} sensitivity histopathology of each of the 64 specimens was analyzed and 100{\%} positive predictive value for identifying recurrent relative to APTw results. Analysis of confirmed recurrent tumor glioma at this cutoff. or treatment effect tissue was used to perform ROC analysis. Conclusions: APTw imaging hyperintensity may be a mark-Results: Eighteen of 21 patients had recurrent tumor, and 3 er of active malignant glioma. It is able to distinguish between had treatment effect on clinical pathology. In 12 patients, there regions of heterogeneous abnormality on anatomic brain MRI were multiple histopathologic assignments confirmed within with high sensitivity and specificity.",
author = "Shanshan Jiang and Eberhart, {Charles G.} and Michael Lim and Heo, {Hye Young} and Yi Zhang and Lindsay Blair and Zhibo Wen and Matthias Holdhoff and Doris Lin and Peng Huang and Huamin Qin and Alfredo Quinones-Hinojosa and Weingart, {Jon D.} and Barker, {Peter B.} and Pomper, {Martin G.} and John Laterra and {Van Zijl}, {Peter C.M.} and Blakeley, {Jaishri O.} and Jinyuan Zhou",
year = "2019",
month = "1",
day = "15",
doi = "10.1158/1078-0432.CCR-18-1233",
language = "English (US)",
volume = "25",
pages = "552--561",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging

T2 - A validation study with image-guided stereotactic biopsy

AU - Jiang, Shanshan

AU - Eberhart, Charles G.

AU - Lim, Michael

AU - Heo, Hye Young

AU - Zhang, Yi

AU - Blair, Lindsay

AU - Wen, Zhibo

AU - Holdhoff, Matthias

AU - Lin, Doris

AU - Huang, Peng

AU - Qin, Huamin

AU - Quinones-Hinojosa, Alfredo

AU - Weingart, Jon D.

AU - Barker, Peter B.

AU - Pomper, Martin G.

AU - Laterra, John

AU - Van Zijl, Peter C.M.

AU - Blakeley, Jaishri O.

AU - Zhou, Jinyuan

PY - 2019/1/15

Y1 - 2019/1/15

N2 - Purpose: To quantify the accuracy of amide proton trans-the same tumor. Of the 64 total specimens, 20 specimens were fer-weighted (APTw) MRI for identifying active glioma after active glioma, 27 mixed active and quiescent glioma, and 17 treatment via radiographically guided stereotactic tissue quiescent/no identifiable tumor. APTw signal intensity and validation. histopathologic assignment, cellularity, and proliferation Experimental Design: Twenty-one patients who were index had significant positive correlations (R ¼ 0.651, referred for surgery for MRI features concerning for tumor 0.580, and 0.458, respectively; all P < 0.001). ROC analysis progression versus treatment effect underwent preoperative with a 1.79% APTw intensity cutoff differentiated active from APTw imaging. Stereotactic biopsy samples were taken from nonactive tumor (AUC of 0.881) with 85.1% sensitivity and regions of interest with varying APTw signal intensities. 94.1% specificity. Analysis of clinical pathology showed the The relationship between final clinical pathology and the mean APTw intensity for each patient had 94.4% sensitivity histopathology of each of the 64 specimens was analyzed and 100% positive predictive value for identifying recurrent relative to APTw results. Analysis of confirmed recurrent tumor glioma at this cutoff. or treatment effect tissue was used to perform ROC analysis. Conclusions: APTw imaging hyperintensity may be a mark-Results: Eighteen of 21 patients had recurrent tumor, and 3 er of active malignant glioma. It is able to distinguish between had treatment effect on clinical pathology. In 12 patients, there regions of heterogeneous abnormality on anatomic brain MRI were multiple histopathologic assignments confirmed within with high sensitivity and specificity.

AB - Purpose: To quantify the accuracy of amide proton trans-the same tumor. Of the 64 total specimens, 20 specimens were fer-weighted (APTw) MRI for identifying active glioma after active glioma, 27 mixed active and quiescent glioma, and 17 treatment via radiographically guided stereotactic tissue quiescent/no identifiable tumor. APTw signal intensity and validation. histopathologic assignment, cellularity, and proliferation Experimental Design: Twenty-one patients who were index had significant positive correlations (R ¼ 0.651, referred for surgery for MRI features concerning for tumor 0.580, and 0.458, respectively; all P < 0.001). ROC analysis progression versus treatment effect underwent preoperative with a 1.79% APTw intensity cutoff differentiated active from APTw imaging. Stereotactic biopsy samples were taken from nonactive tumor (AUC of 0.881) with 85.1% sensitivity and regions of interest with varying APTw signal intensities. 94.1% specificity. Analysis of clinical pathology showed the The relationship between final clinical pathology and the mean APTw intensity for each patient had 94.4% sensitivity histopathology of each of the 64 specimens was analyzed and 100% positive predictive value for identifying recurrent relative to APTw results. Analysis of confirmed recurrent tumor glioma at this cutoff. or treatment effect tissue was used to perform ROC analysis. Conclusions: APTw imaging hyperintensity may be a mark-Results: Eighteen of 21 patients had recurrent tumor, and 3 er of active malignant glioma. It is able to distinguish between had treatment effect on clinical pathology. In 12 patients, there regions of heterogeneous abnormality on anatomic brain MRI were multiple histopathologic assignments confirmed within with high sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=85060053080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060053080&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1233

DO - 10.1158/1078-0432.CCR-18-1233

M3 - Article

C2 - 30366937

AN - SCOPUS:85060053080

VL - 25

SP - 552

EP - 561

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 2

ER -